These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 26402625)

  • 1. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease.
    Sunwoo MK; Jeon S; Ham JH; Hong JY; Lee JE; Lee JM; Sohn YH; Lee PH
    Eur J Neurol; 2014 Jun; 21(6):922-e50. PubMed ID: 24661277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia.
    Bocti C; Swartz RH; Gao FQ; Sahlas DJ; Behl P; Black SE
    Stroke; 2005 Oct; 36(10):2126-31. PubMed ID: 16179569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.
    Smith EE; Egorova S; Blacker D; Killiany RJ; Muzikansky A; Dickerson BC; Tanzi RE; Albert MS; Greenberg SM; Guttmann CR
    Arch Neurol; 2008 Jan; 65(1):94-100. PubMed ID: 18195145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
    Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
    Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status.
    Shin J; Choi S; Lee JE; Lee HS; Sohn YH; Lee PH
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):315-21. PubMed ID: 22228726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment.
    Vipin A; Foo HJL; Lim JKW; Chander RJ; Yong TT; Ng ASL; Hameed S; Ting SKS; Zhou J; Kandiah N
    J Alzheimers Dis; 2018; 66(2):533-549. PubMed ID: 30320575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients.
    Behl P; Bocti C; Swartz RH; Gao F; Sahlas DJ; Lanctot KL; Streiner DL; Black SE
    Arch Neurol; 2007 Feb; 64(2):266-72. PubMed ID: 17296844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of White Matter Hyperintensity Progression with Cognitive Decline in Patients with Amnestic Mild Cognitive Impairment.
    Hirao K; Yamashita F; Tsugawa A; Haime R; Fukasawa R; Sato T; Kanetaka H; Umahara T; Sakurai H; Hanyu H; Shimizu S
    J Alzheimers Dis; 2021; 80(2):877-883. PubMed ID: 33579856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study.
    Kim S; Choi SH; Lee YM; Kim MJ; Kim YD; Kim JY; Park JH; Myung W; Na HR; Han HJ; Shim YS; Kim JH; Yoon SJ; Kim SY; Kim DK
    Int Psychogeriatr; 2015 Dec; 27(12):2069-77. PubMed ID: 26212042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of medial temporal atrophy and white matter hyperintensities on the cognitive functions in patients with Alzheimer's disease.
    Shim YS; Youn YC; Na DL; Kim SY; Cheong HK; Moon SY; Park KW; Ku BD; Lee JY; Jeong JH; Kang H; Kim EJ; Lee JS; Go SM; Kim SH; Cha KR; Seo SW
    Eur Neurol; 2011; 66(2):75-82. PubMed ID: 21778730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study.
    Hessen E; Nordlund A; Stålhammar J; Eckerström M; Bjerke M; Eckerström C; Göthlin M; Fladby T; Reinvang I; Wallin A
    J Alzheimers Dis; 2015; 47(3):619-28. PubMed ID: 26401697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional white matter hyperintensities in normal aging, single domain amnestic mild cognitive impairment, and mild Alzheimer's disease.
    Kim JH; Hwang KJ; Kim JH; Lee YH; Rhee HY; Park KC
    J Clin Neurosci; 2011 Aug; 18(8):1101-6. PubMed ID: 21723730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.